|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004587,
umls-concept:C0005684,
umls-concept:C0021083,
umls-concept:C0030705,
umls-concept:C0080113,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1171362,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-5-4
|
|
pubmed:abstractText |
Bacillus Calmette-Guérin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer (BC), though its efficacy is limited by high recurrence and progression rate. Identification of molecular prognosticators that might be helpful in discriminating between responders and nonresponders to BCG treatment is therefore of major clinical importance; thus we focused on the cell-cycle related retinoblastoma protein (pRB), which had been already investigated in bladder cancer. The goal of our study was specifically to address whether its expression predicts the outcomes of BCG treatment for patients with T1G3 disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1873-2496
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
285-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18976938-Administration, Intravesical,
pubmed-meshheading:18976938-Aged,
pubmed-meshheading:18976938-Aged, 80 and over,
pubmed-meshheading:18976938-Antineoplastic Agents,
pubmed-meshheading:18976938-BCG Vaccine,
pubmed-meshheading:18976938-Disease-Free Survival,
pubmed-meshheading:18976938-Gene Expression Profiling,
pubmed-meshheading:18976938-Humans,
pubmed-meshheading:18976938-Immunohistochemistry,
pubmed-meshheading:18976938-Immunotherapy,
pubmed-meshheading:18976938-Kaplan-Meier Estimate,
pubmed-meshheading:18976938-Middle Aged,
pubmed-meshheading:18976938-Neoplasm Staging,
pubmed-meshheading:18976938-Retinoblastoma Protein,
pubmed-meshheading:18976938-Treatment Outcome,
pubmed-meshheading:18976938-Tumor Markers, Biological,
pubmed-meshheading:18976938-Urinary Bladder Neoplasms
|
|
pubmed:articleTitle |
Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.
|
|
pubmed:affiliation |
Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. luigicormio@libero.it
|
|
pubmed:publicationType |
Journal Article
|
